The Status of CAR T in Hematologic Malignancies – OncLive
OncLive |
The Status of CAR T in Hematologic Malignancies
OncLive Krishna V. Komanduri, MD: Hello, and thank you for joining this OncLive® Peer Exchange® titled “CAR T-Cell Therapy Used in B-Cell Malignancies.” FDA approvals of the first chimeric antigen receptor CAR T-cell therapies mark the beginning of a new era … |
